| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Reslizumab |
| Brand | Cinqaero® |
| Indication | Is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment. |
| Assessment Process | |
| Rapid review commissioned | 23/01/2017 |
| Rapid review completed | 01/03/2017 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended at the submitted price. |
The HSE has approved reimbursement following confidential price negotiations April 2019.